Ipsen is pleased to announce that the US Food and Drug Administration (FDA) has approved a new device to deliver Somatuline® Depot for patients with acromegaly. The enhanced device with Safeâ€™nâ€™Sound® syringe technology will continue to offer a streamlined injection process with its prefilled, low-volume syringe that supports full-dose delivery with no reconstitution requirements.
The syringe is available in 60-mg, 90-mg, and 120-mg doses and will offer several benefits:
The updated design has been available in the European Union since January 2012 and will be available in the US beginning January 2015.
This new device incorporating Safeâ€™nâ€™Sound® syringe technology should be administered by a healthcare professional.
Ipsen is continually looking for ways to improve delivery of the medications that are critical to your patients' care. The enhanced device is one example of this commitment.
Click here for Important Safety Information about Somatuline Depot.
Somatuline® Depot Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
The active substance in Somatuline® Depot is lanreotide acetate, a somatostatin analog that inhibits the secretion of several endocrine, exocrine, and paracrine amines and peptides.
Please click here for additional information about the Somatuline Depot device.
To read the Ipsen Press Release, please click here.